GT Biopharma
Tracked across 13 events · 98 articles · First seen Apr 02, 2026 · Last active Aug 18, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: GT Biopharma announced that results from its US Phase 3 ConfIdeS trial in kidney transplantation have been accepted for an oral presentation at the American Transplant Congress, which is a positive development for the company's imlifidase product.
May 25, 2026 · 6 articles
Business
Impact: GT Biopharma announced positive topline results from its European Post Authorization Efficacy Study for Imlifidase, fulfilling a key requirement for full marketing authorization and boosting its product's market potential.
May 27, 2026 · 6 articles
Business
Impact: GT Biopharma is the company presenting at investor conferences, aiming to attract investors and potentially increase its stock value by showcasing its clinical-stage pipeline and vision.
Jun 02, 2026 · 6 articles
Business
Impact: GT Biopharma granted equity inducement awards to new non-executive employees, which is a positive move for employee retention and attracting talent, potentially boosting its stock price.
May 29, 2026 · 8 articles
Business
Impact: GT Biopharma is the issuer of the offering, raising $125M to fund its oncology pipeline. The offering provides capital but dilutes existing shareholders.
Jul 14, 2026 · 7 articles
Business
Impact: GT Biopharma is the issuer of the inducement options, reflecting its ongoing hiring and compensation practices. The grants are standard and have no significant effect on its valuation.
Jul 23, 2026 · 7 articles
Business
GT Biopharma, a United States — Los Angeles-based biopharmaceutical company, terminated its Chief Medical Officer Richard Graydon on July 17, 2026, citing reasons unrelated to his activities at the company. Shortly thereafter, media reports revealed…
Impact: GT Biopharma is the central company affected, having employed the fugitive executive. The company faces securities investigations and a significant stock price drop, potentially harming its reputation and financial standing.
Jul 20, 2026 · 20 articles
Business
GT Biopharma announced that the first commercial patient in Australia received a living donor kidney transplant following treatment with Idefirix (imlifidase), consistent with the indication approved by the Australia — Therapeutic Goods Administration (TGA). This…
Impact: GT Biopharma achieved a commercial milestone with the first commercial use of Idefirix in Australia, supporting its growth strategy. The company continues to advance regulatory processes, including the FDA BLA review.
Aug 18, 2026 · 6 articles
Business
Impact: GT Biopharma>>> divested the European and MENA rights to Imlifidase for 115 million euros, allowing it to focus on other markets and receive significant payments.
May 19, 2026 · 7 articles
Business
Impact: GT Biopharma licensed its CannEpil therapeutic to Splash Beverage Group globally. GT Biopharma will receive a 15% royalty on net revenue from worldwide sales of CannEpil and had approximately $5 million of its indebtedness forgiven by Mercer Street Global Opportunity Fund.
Jul 06, 2026 · 6 articles
Business
Impact: Verrica Pharmaceuticals has a worldwide license agreement with GT Biopharma for the development and commercialization of VP-315, which may be discussed at the conference.
May 28, 2026 · 6 articles
Business
Impact: GT Biopharma>>> is mentioned as a past company where Steve-O>>> served as Chairman during its acquisition by Johnson & Johnson>>>.
Jun 02, 2026 · 7 articles
100
GT Biopharma treated first patientHansa Biopharma first...
90
United States — Food and Drug Administration accepted application GT BiopharmaHansa Biopharma first...
80
GT Biopharma received approval Australia — Therapeutic Goods AdministrationHansa Biopharma first...
80
Pomerantz LLP investigating claims GT BiopharmaImmix Biopharma executive...
72
GT Biopharma terminated employment Richard GraydonImmix Biopharma executive...
70
Block & Leviton investigating GT BiopharmaImmix Biopharma executive...
60
Portnoy Law Firm launched inquiry GT BiopharmaImmix Biopharma executive...
ERGEN INTELLIGENCE
Track GT Biopharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard